Power3 Medical's CEO Contributes To IVD Technology Magazine

THE WOODLANDS, Texas -- Power3 Medical Products, Inc.’s (OTCBB: PWRM) CEO, Steven Rash has contributed an article to the April 2008 issue of IVD Technology magazine. Power3 Medical is a leading proteomics company specializing in the development and commercialization of diagnostic tests for the early detection of breast cancer and neurodegenerative diseases.

The article, entitled “Fueling Proteomic Diagnostics,” outlines how, “biomarkers hold the most promise for generating rapid, accurate, and reasonably priced early-stage cancer diagnostics.” Mr. Rash writes, “In theory, a sensitive biomarker-based test can detect a tumor before it becomes visible through physical examination or imaging. As a result, biomarkers have become indispensable in drug development, where clinical endpoints are frequently measured by the attainment of up- or down-regulated proteins, genes, or metabolites. Biomarkers may also serve as signals for a drug’s effectiveness and may eventually fuel the growth of personalized medicine.”

“Power3 Medical is gratified that the editors of IVD Technology invited us to share our insights in the proteomics space,” said Mr. Rash. “It is particularly rewarding that the biotechnology community has acknowledged Power3’s efforts and advancements in proteomic diagnosis through blood-based testing.”

Power3 is currently pursuing ongoing commercialization efforts for its biomarkers and its blood serum test, BC-SeraPro™ for the early diagnosis of breast cancer, and NuroPro™, a blood serum test for the early diagnosis of neurodegenerative diseases. The company currently has several ongoing clinical validation trials at multiple national and international sites. The BC-SeraPro™ breast cancer test is commercially available in several Middle Eastern countries through a distribution agreement. The NuroPro™ test for neurodegenerative diseases will follow soon thereafter.

About IVD Technology
IVD Technology is the only trade journal designed exclusively for manufacturers of in vitro diagnostic products. Written by leading experts in their fields, IVDT’s peer-reviewed articles cover a wide range of technical and regulatory topics. The publication’s primary focus is on diagnostics technologies--including research, development, and manufacturing.

IVDT articles contain authoritative information on all aspects of manufacturing immunoassays, nucleic-acid-based diagnostics, clinical chemistry tests, and related instrumentation. Each issue of the publication covers applied technology issues such as antibody development, substrate selection, purification, lyophilization, filtration, QA/QC, raw materials specification, clinical testing, and R&D.

Regular editorial coverage offers insights into the implications of new and pending regulations, the behind-the-scenes workings of the regulatory process, and the legal issues affecting product development and marketing. IVDT also analyzes critical business and marketing issues such as product liability, emerging markets, and other key trends.

About Power3 Medical Products
Power3 Medical Products, Inc. (OTCBB: PWRM), is a leading proteomics company engaged in the commercialization of protein biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets for cancer and neurodegenerative diseases. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 has signed its first distribution agreement to provide its blood serum diagnostic for breast cancer, BC-SeraPro™, in twelve Middle Eastern countries before the end of 2007. Power3 operates a state-of-the-art CLIA certified proteomics laboratory in The Woodlands (Houston), Texas. The Company is preparing to commercialize its IP portfolio, centering on the 543 biomarkers the Company has discovered from a broad range of diseases as the basis of blood-based tests for breast cancer, ALS, Alzheimer’s, and Parkinson’s Diseases.